Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Nada H. Mohammed"'
Publikováno v:
Pharmaceuticals, Vol 17, Iss 10, p 1275 (2024)
Background/Objectives: Nintedanib (NTD), a triple tyrosine kinase receptor inhibitor, is the recommended first-line tackling option for idiopathic pulmonary fibrosis (IPF). Nevertheless, the adequacy of NTD is curtailed by issues associated with its
Externí odkaz:
https://doaj.org/article/9384c8f7547a4abe8c429dd41f8f2719
